Polysialic acid (PSA) is a large, negatively charged, linear homopolymer of alpha2-8-linked sialic acid residues. It is generated by two polysialyltransferases and attached to Nand/or O-linked glycans, and its main carrier is the neural cell adhesion molecule (NCAM). PSA controls the development and regeneration of the nervous system by enhancing cell migration, axon pathfinding, synaptic targeting, synaptic plasticity, by regulating the differentiation of progenitor cells and by modulating cell-cell and cell-matrix adhesions. In the adult, PSA plays a role in the immune system, and PSA mimetics promote functional recovery after nervous system injury. In search for novel small molecule mimetics of PSA that are applicable for therapy, we identified idarubicin, an antineoplastic anthracycline, and irinotecan, an antineoplastic agent of the topoisomerase I inhibitor class, as PSA mimetics using a competition enzyme-linked immunosorbent assay. Idarubicin and irinotecan compete with the PSA-mimicking peptide and colominic acid, the bacterial analog of PSA, for binding to the PSA-specific monoclonal antibody 735. Idarubicin and irinotecan stimulate neurite outgrowth and survival of cultured cerebellar neurons after oxidative stress via protein kinase C and Erk1/2 in a similar manner as colominic acid, whereas Fyn, casein kinase II and the phosphatase and tensin homolog 0 ,6-diamidino-2-phenylindole; DMEM, Dulbecco's modified Eagle medium; DMSO, dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent assay; epirubicin, (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl] oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione hydrochloride; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HRP, horseradish peroxidase; idarubicin, (7S,9S)-9-acetyl-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-8, 10-dihydro-7H-tetracene-5,12-dione hydrochloride; irinotecan, (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-314-dioxo-1H-pyrano [3 0 ,4 0 :6,7] indolizino [1,2-b] quinolin-9-yl-[1,4 0 -bipiperidine]-1 0 -carboxylate monohydrochloride trihydrate; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NCAM, neural cell adhesion molecule; OPD, o-phenylenediamine dihydrochloride; PBS, phosphate-buffered saline solution; PBST, phosphate-buffered saline solution containing Tween-20; PDL, poly-D-lysine; PLL, poly-L-lysine; PLSD, protected least significant difference; PPT, protein phosphotyrosine phosphatase; PSA, polysialic acid; PTEN, phosphatase and tensin homolog; SD, standard deviation; SEM, standard error of the mean; SN-28, 7-ethyl-10-hydroxy-camptothecin.
oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione hydrochloride; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HRP, horseradish peroxidase; idarubicin, (7S,9S)-9-acetyl-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-8, 10-dihydro-7H-tetracene-5,12-dione hydrochloride; irinotecan, (S) -4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-314-dioxo-1H-pyrano 0 -bipiperidine]-1 0 -carboxylate monohydrochloride trihydrate; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NCAM, neural cell adhesion molecule; OPD, o-phenylenediamine dihydrochloride; PBS, phosphate-buffered saline solution; PBST, phosphate-buffered saline solution containing Tween-20; PDL, poly-D-lysine; PLL, poly-L-lysine; PLSD, protected least significant difference; PPT, protein phosphotyrosine phosphatase; PSA, polysialic acid; PTEN, phosphatase and tensin homolog; SD, standard deviation; SEM, standard error of the mean; Polysialylation is a post-translational modification executed by two polysialyltransferases (Rutishauser 2008) . The polysialyltransferases generate a long homopolymer of a2,8-linked N-acetylneuraminic acid units, which is mostly attached to the neural cell adhesion molecule (NCAM). Less prominent carriers of polysialic acid (PSA) are SynCAM-1, the polysialyltransferase ST8SiaII, neuropilin-2, the chemokine receptor CCR7, and the scavenger receptor CD36 (M€ uhlenhoff et al. 2013; Hildebrandt and Dityatev 2015; Kiermaier et al. 2016) . Polysialylation mainly controls the developmental plasticity of the vertebrate nervous system by modulating neural cell migration, axon pathfinding and synaptic targeting (Schnaar et al. 2014) . In the adult nervous system, the expression of PSA becomes restricted to regions of neuronal and glial plasticity, such as the dentate gyrus of the hippocampus, where it enables synaptic plasticity (Rutishauser 2008; Bonfanti and Theodosis 2009; Senkov et al. 2012) . PSA attached to a transmembrane proteolytic NCAM fragment was shown to enter the cell nucleus of cultured cerebellar granule neurons and of neurons in different brain regions of adult mice where PSA-carrying NCAM contributed to the regulation of clock-related gene expression and of the circadian rhythm (Westphal et al. 2016) . Recent evidence also suggests an involvement of PSA during immune responses (Curreli et al. 2007; Drake et al., 2008; Rey-Gallardo et al. 2010; Kiermaier et al. 2016) . Furthermore, PSA is aberrantly re-expressed on many tumors of neuroendocrine origin and promotes cancer growth and metastasis by a mechanism that has yet to be described (Suzuki et al. 2005; Falconer et al. 2012) . A transient reexpression of PSA was also detected in neurons and glial cells in different lesion models using adult animals (Brezun and Daszuta 2000; Bonfanti 2006) , and levels and localization of PSA were found to be critical for early peripheral nerve regeneration (Jungnickel et al. 2009 ). Re-introduction of PSA into the adult nervous system by transducing the tissue with PSA, by injecting lentiviral vectors, or by implanting PSA-over-expressing Schwann cells into the spinal cord after injury, enhanced regeneration of sensory axons. Furthermore, PSA-over-expressing Schwann cells showed improved migration and promoted axonal regeneration, remyelination and functional recovery (Lavdas et al. 2006; Zhang et al. 2007; Luo et al. 2011; Ghosh et al. 2012) . Similarly, application of PSA mimicking peptides or small molecules improved functional recovery after spinal cord and femoral nerve injury (Marino et al. 2009; Mehanna et al. 2009 Mehanna et al. , 2010 Bushman et al. 2014; Pan et al. 2014; Saini et al. 2016) . In addition, it is assumed that the increased expression of PSA in the hippocampus and entorhinal cortex of patients suffering from temporal lobe epilepsy, as well as in the molecular layer of the dentate gyrus in patients with Alzheimer's disease indicates attempts of repair and disease-related plasticity (Mikkonen et al. 1998 (Mikkonen et al. , 1999 . These favorable effects of PSA overproduction and application of PSA mimetics make this carbohydrate a promising candidate for the development of novel therapeutic strategies to treat nervous system injuries and diseases.
Treatment with PSA-transducing viruses or application of PSA-expressing cells as a therapeutic strategy has the disadvantage that PSA can be cleaved in vivo by neuraminidases and sialidases, such as sialidase NEU4, which is highly expressed in the central nervous system (Takahashi et al. 2012) . Furthermore, PSA is difficult to isolate, purify or produce from biological sources, especially when a defined PSA with a certain number of sialic acid residues is needed. Peptide mimetics of PSA discovered by screening of phage display libraries with PSA monoclonal antibodies (Torregrossa et al. 2004; Mehanna et al. 2009 ) promoted functional recovery and plasticity after injury of the murine peripheral and central nervous systems (Marino et al. 2009; Mehanna et al. 2009 Mehanna et al. , 2010 . However, peptides can be more instable in vivo and display a short half-life because of enzymatic degradation by proteases and fast renal clearance (Sato et al. 2006; Li et al. 2015; Penchala et al. 2015) . Therefore, we searched for novel, small organic compounds that mimic PSA structurally and functionally and are approved pharmaceuticals. These compounds are assumed to provide a longer half-life, stability and safety and can be easier and cheaper to synthesize. Their toxicology is known for certain indications and re-purposing of these drugs should allow a facilitated procedure for therapeutic acceptance. We assumed that these compounds will trigger the same beneficial functions as PSA in vitro and in vivo and that they will signal via the same pathways as PSA. We identified idarubicin, a clinically effective synthetic anthracycline analog used in the treatment of several human neoplasms, and irinotecan, an antineoplastic agent of the topoisomerase I inhibitor class used for treatment of small cell lung cancer and advanced colorectal cancer, as novel PSA mimetics and tested their function and signaling pathways in vitro using cultures of murine and rat primary neurons of central nervous system origin. Our results show that idarubicin and irinotecan bind to the PSA-specific monoclonal antibody 735, modulate in vitro outgrowth and survival of cerebellar granule neurons in a manner similar to colominic acid, the bacterial analog of PSA, and signal via protein kinase C (PKC) and extracellular regulated kinase 1/2 to stimulate neuronal survival and neurite outgrowth. Additionally, Scr family kinases, casein kinase II and the phosphatase and tensin homolog (PTEN) are involved in the induction of neurite outgrowth. These novel results show that the structure and function of PSA can be mimicked by the small organic compounds irinotecan and idarubicin and that these compounds trigger the same intracellular signaling cascades as PSA to promote neurite outgrowth and neuronal survival.
Materials and methods

Antibodies and reagents
Chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA) if not indicated otherwise. (7S,9S)-9-acetyl-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione hydrochloride (idarubicin hydrochloride; idarubicin), (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano 3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3- ELISA screening of a small organic compound library for PSA mimetics The NIH Clinical Collection 1 Library containing 446 small organic compounds was screened for molecules structurally mimicking PSA using competitive enzyme-linked immunosorbent assay (ELISA) as described . In brief, catalase-coupled PSAmimicking peptides were immobilized on the surface of 384-well flat-bottom microtiter well plates (3 lg/mL; 25 lL/well), which was then washed with phosphate-buffered saline (PBS) solution and blocked with 1% bovine serum albumin for 1 h at 22°C. PSAspecific antibody 735 (0.1 lg/mL; 25 lL/well) incubated with either PBS solution, pH 7.4 (PBS) serving as a negative control, PBS and 1% dimethyl sulfoxide (DMSO) serving as a solvent control, colominic acid (CA; 10 lM), the bacterial analog of PSA, serving as a positive control or 10 lM of the NIH library compounds in DMSO were then added to the PSA-mimicking peptide-containing wells. Following five subsequent washes with 0.5% Tween-20 diluted in PBS (PBST), addition of HRP-coupled secondary antibody (1 : 5000 in PBS), visualization with 5 min of incubation with 25 lL of 0.5 mg/mL o-phenylenediamine dihydrochloride and termination of the resultant reaction with 25 lL 2.5 M H 2 SO 4 , absorbance was quantified at 490 nm using an ELISA reader (EnVision Plateworks software; Perkin Elmer, Waltham, MA, USA). Compounds were considered to be PSA mimetics, when they competed with a PSA mimicking peptide for binding to the PSA-specific antibody (reduction in signal intensity by more than 30%). Confirmation that molecules producing hits in the screening were true structural PSA mimetics was obtained by testing their ability to bind to antibody 735 in both a specific and concentration-dependent manner. Competition ELISA was carried out, as described, using antibody 735 pre-incubated with increasing concentrations of the compounds or a control peptide, nitrendipine .
In vitro neurite outgrowth assay and cell migration Primary cerebellar granule neurons were prepared from wild-type mice or rats as described (Loers et al. 2005) . For neurite outgrowth studies, cells were seeded at a density of 125 000 cells/mL (250 lL each well) in 0.01% poly-D-lysine-coated 48-well Falcon tissue culture plates (ThermoFisher Scientific). Cells were allowed to settle down for 1 h and then incubated with the test compounds, solvent or positive controls for 23 h at 37°C with 5% CO 2 and 90% humidity, fixed with 2.5% glutaraldehyde for 30 min and stained with 1% toluidine blue and 0.1% methylene blue in 1% Natetraborate. Neurites were imaged and quantified using an AxioObserver.A1 microscope (Carl Zeiss, Oberkochen, Germany) with a 209 objective and AxioVision 4.6 software (Carl Zeiss). The longest neurite lengths were measured from the edge of the cell body to the end of the process, taking into account only neurites with a length equal to or greater than the diameter of the soma from which they originated and those that showed no contact with other neurites or cell bodies. Measurements were taken from 50 cells in each of two wells per condition carried out in three independent experiments. All measurements were conducted using ImageJ software (National Institutes of Health). Cerebellar explants were prepared as described and migration of neurons was determined from at least 12 explants per treatment and experiment (Jakovcevski et al. 2009 ).
IMR-32 cells were subcultured by trypsinization (0.01% in PBS) and maintained in 12-or 24-well plates according to the requirement of the experiment. Migration of IMR-32 cells was assessed using a scratch injury assay performed according to Etienne-Manneville (2006) with slight modifications . Confluent IMR-32 cell monolayers were wounded by scratching with a sterile 22-gauge needle, resulting in a cell-free cleft~800 lm wide. Directly after scratching, compounds were added and the cell-free areas were determined microscopically with a 109 objective. Time point zero indicates the maximal scratch size determined directly after the injury (100% gap size). To analyze the migration of cells into the cell-free/scratched area, pictures of the gap were taken 24 h after scratch injury using a phase contrast microscope (Nikon TE2000, Melville, NY, USA). From these images, the size of the remaining cell-free area, as well as the distances the cells migrated into the cell-free area, were measured using the Image-Pro Plus software (Media Cybernetics, Silver Spring, MD, USA). The cellfree area was determined from six wells per treatment group.
Cell survival A cell survival assay was conducted as described (Loers et al. 2005) with slight modifications. Briefly, cerebellar granule neurons cultured from P6-P7 mice were seeded at a density of 1 9 10 6 cells/mL (250 lL each well) in 0.01% poly-D-lysine-coated 48-well flatbottom tissue culture plates (ThermoFisher Scientific) and maintained at 37°C with 5% CO 2 and 90% humidity overnight. Subsequently, cells were treated with inhibitors, solvent control or left untreated. Twenty minutes after inhibitor addition, mimetics at different concentrations and controls (DMSO; CA) were added to the neurons, which were incubated for additional 30 min. Oxidative stress was then induced by the addition of 10 lM H 2 O 2 for 24 h. Afterwards, live and apoptotic cells were stained for 1 h at 37°C using 1 lg/mL calcein-AM and 1 lg/mL propidium iodide, and then fixed with 4% formaldehyde for 30 min at room temperature. The cells were washed three times with PBS at 22°C and imaged using a Zeiss Axiovert 200M inverted transmitted-light microscope (Carl Zeiss). A count of living cells and apoptotic cells was taken from four images for each of three wells per condition using ImageJ. Experiments were carried out three independent times and for each experiment all images were processed the same way. First, the contrast/brightness threshold was adjusted manually until there was a clear shape of the cell somas visible. Subsequently, the background noise was eliminated using the despeckle and erode functions. To return the remaining cells back to their original shape, the dilate function was used. Finally, the watershed function was implemented to improve accuracy before the cells were counted using the analyze particles function. Cell numbers of living and apoptotic cells were summarized for each image and the percentage of living cells was calculated.
To determine IMR-32 cell survival, cells were seeded at a density of 15 9 10 3 cells/mL in 96-well plates, and cultured for 2 h to allow for cell adhesion and treated with the test compounds at different concentrations (0.5 nM-5 lM). Cells were cultured for additional 72 h and then stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and 4 0 ,6-diamidino-2-phenylindole to determine the number of live cells . The cell number was determined from three wells for each treatment group.
Cell signaling experiments
Cell signaling that is essential for enhanced neurite outgrowth and neuronal survival after colominic acid (CA) and PSA mimeticinduced stimulation was analyzed using cerebellar granule neurons of P6-P7 mice. Neurons were pre-treated for 20 min with different signal transducer molecule inhibitors (120 nM KT5720, PKA inhibitor; 100 lM HBDDE, PKC inhibitor; 220 nM (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid, casein kinase II inhibitor; 4 lM ERK inhibitor III; 40 nM PP121, Src family inhibitor; 1.2 lM 1-Naphthyl PP1, Src family inhibitor; 28 nM bpV(HOpic), PTEN inhibitor) before the mimetics or CA were added. Three independent neurite outgrowth and cell survival experiments were then performed as described to determine which inhibitors alter the effects of CA and/or the mimetics on these cellular processes.
Immunocytofluorescence staining Cells were fixed with 4% formaldehyde and permeabilized with 0.3% Triton X-100 in PBS (PBST). For dual immunostaining, cells were incubated together with antibodies against PSA and NCAM in blocking solution (PBS with 2% bovine serum albumin; 1 : 250) at 4°C overnight. After three washes with PBS, cells were incubated with anti-mouse IgM 488 and anti-mouse IgG 546 antibodies in blocking solution for 2 h at 22°C and counter-stained with 4 0 ,6-diamidino-2-phenylindole to visualize nuclei. Images were captured using a confocal microscope (Nikon A1R; Nikon Corporation, Tokyo, Japan) and relative immunofluorescence intensities were determined using NIS elements AR analysis software version 4.11.00 (Nikon Corporation).
Cell stimulation and western blot analysis Cerebellar neurons were seeded at a density of 2 9 10 6 cells/well into poly-L-lysine-coated 6-well culture plates and maintained for 16-24 h in defined serum-free medium. (Makhina et al. 2009 ) and membranes were incubated with primary antibodies [anti-PSA 735 (1 : 2000) , anti-NCAM (1 : 1000), or/and anti-glyceraldehyde 3-phosphate dehydrogenase (1 : 1000)] followed by incubation with HRP-conjugated secondary antibodies (1 : 20 000) for 1 h at 22°C. Immunoreactive bands were visualized using the advanced chemiluminescent substrate (GE Healthcare, Little Chalfont, UK) and a gel imaging system (ImageQuant LAS 4000; GE Healthcare).
Statistics
An independent scientist encrypted all chemicals which were used for the different treatments, and experiments were performed and analyzed in a blinded manner. Average values and standard error of the mean (SEM) were calculated from a pool of at least three independent experiments and statistical comparisons were conducted by one-way analysis of variance (ANOVA) followed by HolmSidak or by Fisher's protected least significant difference post hoc tests using StatView (Scientific Computing, Cary, NC, USA) and Excel (Microsoft, Redmond, WA, USA).
Results
Idarubicin and irinotecan compete with a PSA-mimicking peptide for binding to anti-PSA antibody 735 To identify novel PSA mimicking compounds, the NIH Clinical Collection 1 Library was screened for compounds that interfere with binding of the PSA receptor site of antibody 735 to the PSA-mimicking peptide coupled to catalase. Two of these compounds that were able to bind to antibody 735 were idarubicin and irinotecan. To verify the results of the initial screen, a competition ELISA was performed using different molar concentrations (1-100 lM) of idarubicin and irinotecan, and nitrendipine as a control compound. Idarubicin and irinotecan reduced binding of antibody 735 to PSA-mimicking peptide coupled to catalase as well as colominic acid, the bacterial analog of PSA, coupled to catalase in a concentration-dependent manner (Fig. 1) . The maximal effect was observed at a 60-100 lM compound concentrations. At a 100 lM concentration, idarubicin reduced binding of the PSA-mimicking peptide to antibody 735 by 37% and irinotecan by 45% respectively. Nitrendipine, which served as a control compound, did not significantly impede antibody binding to colominic acid. The reduction in the observed signal intensity is probably because of the presence of the solvent DMSO which reduced binding of the antibody 735 to the PSA-mimicking peptide in a similar manner as seen for nitrendipine. Free colominic acid maximally reduced binding of the PSA-mimicking peptide to antibody 735 by 48-51% at 20-100 lM concentrations. The results show that irinotecan is as potent as colominic acid in binding to the PSA-specific antibody 735, while idarubicin is slightly less potent.
Idarubicin and irinotecan induce neurite outgrowth and neuronal survival
To analyze whether idarubicin and irinotecan also function in a similar manner as PSA, we determined neurite outgrowth and neuronal survival of PSA-responsive cerebellar granule neurons. Since both compounds are topoisomerase inhibitors that generate DNA strand breaks and induce apoptosis, IMR-32 neuroblastoma cells were used to determine the compound concentrations that can be applied to proliferating cells without inducing cell death. Application of 0.5 nM to 1 lM irinotecan did not alter cell survival, but higher concentrations induced cell death (Fig. 2a) . This result shows that treatment of post-mitotic and proliferating cells is not deleterious at concentrations in the nanomolar range or at even lower concentrations. Therefore, 1 pM to 100 nM irinotecan and idarubicin were applied to cultured cerebellar granule neurons to test their effect on neurite outgrowth. Inrinotecan and idarubicin stimulated neurite outgrowth in a concentration-dependent manner, with the highest stimulatory effects seen at a 1 nM concentration of idarubicin and 10 pM irinotecan, which reached similar values as colominic acid treatment and treatment with the previously identified PSA-mimicking compound epirubicin (Fig. 2b) . At concentrations higher than 1 nM irinotecan and idarubicin showed a reduced effect on neurite outgrowth leading to a bell-shaped response curve as it was previously observed for the PSA mimetics epirubicin and vinorelbine ). PSA has been described to beneficially influence the survival of glial and neuronal cells. PSA-NCAM was reported to support survival of injured retinal ganglion cells (Lobanovskaya et al. 2015) . PSA-expressing Schwann cells survived better after transplantation into the lesioned spinal cord than control cells (Luo et al. 2011) . Colominic acid, a PSA-mimicking peptide, and the PSA-mimicking compound tegaserod were shown to increase the survival of stressed motor neurons and cerebellar granule neurons (Bushman et al. 2014) . Therefore, we investigated whether application of irinotecan and idarubicin to cultured granule cells can protect the cells from oxidative stress. Idarubicin and irinotecan enhanced neuronal survival at concentrations of 0.1 pM to 100 nM with strongest protection of cells seen at 1 nM concentration (Fig. 3) . Higher compound concentrations were less effective in supporting cell survival, an effect also observed in cell survival assays with the PSA mimetics epirubicin and vinorelbine ). The prosurvival effect of idarubicin was comparable to the protective effects achieved by treatment of neurons with colominic acid and epirubicin, whereas irinotecan was slightly less effective.
Irinotecan and idarubicin do not alter cell migration
Since PSA-expressing Schwann cells and stem cells were shown to migrate farther in lesioned tissue than control cells, and since treatment of IMR-32 cells and cerebellar neurons with colominic acid and the PSA mimetic 5-nonyloxytryptamine enhanced migration of these cells , we were interested in determining if the novel PSA mimetics might also influence cell migration. A scratch injury assay was performed using IMR-32 cells. The cells were treated with and without irinotecan and cell migration into the cell-free wound area was monitored. Results showed that in contrast to PSA, colominic acid and 5-nonyloxytryptamine, irinotecan did not alter cell migration of IMR-32 cells (Fig. 4a) . Furthermore, irinotecan and idarubicin did not enhance the migration of cerebellar neurons out of cerebellar explants at femto-or picomolar concentrations (Fig. 4b) but reduced migration at nanomolar concentrations (data not shown). It is thus likely that irinotecan and idarubicin act more as cell cycle inhibitors than as PSA mimetics under these experimental conditions.
Idarubicin and irinotecan stimulate neurite outgrowth and survival of cerebellar neurons via protein kinase C and Erk1/2 As a next step, we analyzed whether idarubicin and irinotecan treatment activates the same signaling pathways as PSA and PSA-NCAM. NCAM was shown to activate cAMP-dependent PKA as well as PKC, phosphatidylinositol-4,5-bisphosphate 3-kinase, Ca 2+ /calmodulin-dependent protein kinase II (CaMKII), Fyn and extracellular regulated kinases (Erk) 1/2 (Loers and Schachner 2007; Maness and Schachner 2007) . Additionally, NCAM interacts with the fibroblast growth factor receptor, which leads to the activation of phospholipase C and PKC, while PSA was shown to interact with myristoylated alanine-rich C kinase substrate through the plasma membrane (Theis et al. 2013) . It was therefore conceivable that idarubicin and irinotecan would activate the same signaling molecules, if they are true mimetics of PSA. Indeed, treatment of cerebellar neurons with inhibitors of PKC, casein kinase II (CKII), Src/Fyn and PTEN reduced the neurite outgrowth effect of idarubicin and irinotecan (Fig. 5) . Interestingly, only the PKC inhibitor and Erk inhibitor significantly reduced the pro-survival effect of idarubicin and irinotecan as well as of colominic acid, whereas PKA, CKII, Src/Fyn and PTEN inhibitors did not reduce the prosurvival effect of the compounds or colominic acid (Fig. 6 ).
Idarubicin and irinotecan enhance expression of PSA and NCAM In addition to activating signaling pathways, PSA mimetics were shown to enhance the endogenous expression of PSA and NCAM . To determine whether idarubicin and irinotecan are also able to up-regulate PSA and NCAM expression, IMR-32 cells were treated with compounds for 24 h and then stained with antibodies against PSA and NCAM. Alternatively, cerebellar neurons were treated with compounds for 24 h, and cell lysates were then probed with PSA and NCAM antibodies. Results showed that irinotecan, idarubicin and colominic acid enhanced the expression of PSA and NCAM in a similar manner as the previously described PSA mimetics, 5-nonyloxytryptamine and vinorelbine (Fig. 7) .
The combined results indicate that idarubicin and irinotecan act as PSA mimetics and stimulate neurite outgrowth and neuronal survival via PKC and Erk1/2.
Discussion
With recent advances in the identification of glycan receptors, discovery of glycomimetics, construction of synthetic glycans for drug delivery and drug design, glycans and glycomimetics have become increasingly attractive for therapeutic applications (Mehanna et al. 2010; Irintchev et al. 2011; Masand et al. 2012; Prost et al. 2012; Rowlands et al. 2015; Cunha and Grenha 2016; Hockl et al. 2016) . One important drug target and glycan for drug delivery is PSA. PSA was shown to be involved in invasive (Falconer et al. 2012) , schizophrenia and depression (Senkov et al. 2012) , synaptic plasticity (Bonfanti 2006; Bonfanti and Theodosis 2009; Senkov et al. 2012) , development of the nervous system (Bonfanti 2006; Rutishauser 2008; Franceschini et al. 2010) and neuroregeneration (Mehanna et al. 2010; Ghosh et al. 2012; Masand et al. 2012) . PSA-carboxymethyl chitosan hydrogel, amphiphilic PSA derivatives and PSA grafted with polycaprolactone are currently being explored as promising drug-delivery systems (Deepagan et al. 2013; Wilson et al. 2014; Wu et al. 2015) . Thus, manipulation of PSA functions and application of PSA mimetics is likely to be of important therapeutic value for treatment of nervous system injuries and neurological disorders.
In our search for PSA mimetics with known toxicology and pharmacological profiles, we identified idarubicin and irinotecan as novel PSA-mimicking compounds. Irinotecan (drug name Onivyde â ) is the hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Irinotecan is a prodrug that is converted to a biologically active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-28), by a carboxylesterase-converting enzyme. SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death (National Cancer Institute; http://ncit.nci.nih.gov/ncitbrowser/ConceptReport. jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code= Fig. 5 Cell signaling essential for neurite outgrowth that is triggered by idarubicin, irinotecan, epirubicin and colominic acid (CA). Bar diagram displays the average longest neurite length (mean + SEM) of rat cerebellar granule neurons pre-treated with different signal transducer molecule inhibitors (KT 5720 (protein kinase A), HBDDE (protein kinase C), TBCA (casein kinase II), Erk inhibitor III (Erk), PP121 (Src), 1-Naphthyl PP1 (Fyn), bpV(HOpic) (phosphatase and tensin homolog)) and untreated cells or cells treated with 1 nM idarubicin or epirubicin, 0.01 nM irinotecan or 30 lg/mL CA. The hash sign shows a significant difference between the untreated group (control; À) and the groups treated only with PSA mimetics or CA (#p < 0.001). Asterisks signify statistically significant differences within the groups as determined by one-way ANOVA with Fisher's protected least significant difference (PLSD) test (n = 300 cells from six wells out of three independent experiments; F = 36.575 p < 0.0001; PLSD *p < 0.05). Representative phase contrast images of untreated explants (À) and explants treated with idarubicin, irinotecan or nitrendipine (negative control) (all 100 fM) 24 h after treatment. Histogram shows the number of migrating cells out of cerebellar explants (mean + SD) from control, irinotecan-, idarubicin-or nitrendipine-treated explants at indicated concentrations 24 h after treatment. The experiment was performed independently four times and at least 12 explants were analyzed in each experiment (n = 4). No statistically significant differences between control and treated explants were seen (p > 0.05, one-way ANOVA with Holm-Sidak post hoc test). Scale bar, 50 lm. C1381). Idarubicin is an anthracycline antineoplastic antibiotic. Idarubicin (drug names idamycin preservative-free solution and idarubicin hydrochloride) intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and, ultimately, interfering with RNA and protein synthesis (National Cancer Institute; http://ncit.nci. nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_ Thesaurus&ns=NCI_Thesaurus&code=C1587). We could show that in addition to their published action as topoisomerase inhibitors, both compounds bind to PSA-specific antibody 735 and stimulate neurite outgrowth and neuronal survival in a concentration-dependent manner. The observed bell-shaped response curves were also seen when using the previously described PSA mimetics epirubicin and vinorelbine suggesting that these results are probably a result of the cell cycle inhibiting effect of the compounds at higher concentrations. Furthermore, idarubicin and irinotecan enhanced the expression of PSA and NCAM. This treatment most likely increased PSA and NCAM levels by contributing to the effect of idarubicin and irinotecan on neurite outgrowth and neuronal survival by enhancing the stimulation of PSAand NCAM-mediated signaling pathways.
These functions of idarubicin and irinotecan are likely mediated by PKC, a known downstream signaling 1 nM idarubicin, irinotecan or epirubicin or 30 lg/mL CA followed by cell death induction with H 2 O 2 . For each treatment and experiment, six wells were used and the experiment was repeated four times (n = 4). The hash sign shows significant difference between the untreated group (À; À H 2 O 2 ) and the stressed group (À; + H 2 O 2 ) or the stressed groups treated with compounds (À; + H 2 O 2 ; idarubicin/irinotecan/CA) and the stressed groups treated with inhibitors and compounds (inhibitor; + H 2 O 2 ; idarubicin/irinotecan/CA) ( # p < 0.001). Asterisks signify statistically significant difference compared to the hydrogen peroxide-treated group as determined by one-way ANOVA with test Holm-Sidak post-hoc test (*p < 0.05).
component of NCAM signaling pathways shown to be important for NCAM-mediated neurite outgrowth (Kolkova et al. 2005) . In addition, PKC regulates polysialyltransferase activity and the NCAM polysialylation state (Gallagher et al. 2001) . Therefore, activation of PKC by idarubicin and irinotecan could both stimulate signaling pathways and provide a feedback mechanism to regulate PSA expression. Altered PSA levels could then further influence NCAM (untr) or treated with 1 nM irinotecan (irino), 1 nM idarubicin (ida), 1 nM nitrendipine (nitr; control compound), 30 lg/mL colominic acid (CA) or DMSO (formulation control) for 24 h, lysed and subjected to western blot analysis (IB) with antibodies against PSA and NCAM. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was analyzed to control for loading. PSA and NCAM levels were quantified by densitometry and normalized to the GAPDH levels. A representative immunoblot out of six experiments is shown. Histogram shows data representing mean values + SD from six independent experiments (n = 6) representing the levels of PSA and NCAM in compound-treated cells normalized to GAPDH levels and compared to PSA and NCAM levels in control cells. *p < 0.05, one-way ANOVA with Holm-Sidak post hoc test.
signaling, as shown in recent in vitro studies (R€ ockle et al. 2008; Eggers et al. 2011) . Here, we also show that the neurite outgrowth stimulatory effect of irinotecan and idarubicin depends on the activation of the Src non-receptor tyrosine kinase family members, Erk1/2 and casein kinase II (CKII). This is in agreement with previous studies demonstrating that NCAM-mediated neurite outgrowth was abolished by pharmacological inhibition of Src-family kinases (Kolkova et al. 2000) and NCAM clustering on the cell surface by means of NCAM antibodies resulted in transient Fyn phosphorylation (Beggs et al. 1997) . The activation of NCAM-mediated downstream signaling led to phosphorylation and stimulation of Erk1 and Erk2 (Schmid et al. 1999; Kolkova et al. 2000) . Similar pathways were shown to be activated in primary neurons by application of the PSA mimetics 5-nonyloxytryptamine, vinorelbine and epirubicin . It is noteworthy in this context that EndoN-mediated removal of PSA from human neuroblastoma cells initiated NCAM interactions at cell-cell contacts and resulted in reduced cell proliferation and, in parallel, activation of the Erk1/2 pathway (Cavallaro et al. 2001; Francavilla et al. 2009 ). Phosphorylation of growth-associated protein GAP-43 by PKC, as well as by CKII, was shown to be important for NCAM-induced neurite outgrowth (Korshunova et al. 2007) , while CKI was identified as a protein kinase able to phosphorylate NCAM (Mackie et al. 1989) . Thus, it is conceivable that irinotecan and idarubicin as PSA mimetics also signal via CKII, Erk1/2 and Scr family kinases to induce neurite outgrowth. Interestingly, idarubicin and irinotecan also activated PTEN to induce neurite outgrowth, but an involvement of PTEN in NCAM or PSA signaling or an association of PTEN with NCAM has not yet been reported. From the protein family of cell adhesion molecules, only L1 and CHL1 have been shown to influence PTEN expression. L1 was shown to bind to CKIIa via its intracellular domain and to trigger neuroprotection via inhibition of PTEN and p53. Application of a CKII inhibitor or transfection with CKIIa siRNA increased levels of PTEN and p53 in primary neurons (Wang and Schachner 2015) . CHL1 was shown to regulate phosphorylation of the serotonin 2c receptor and its association with PTEN and barrestin 2 (Kleene et al. 2015) . Therefore, NCAM, with its attached glycan PSA, might also influence PTEN functions, which might be reflected in our findings with irinotecan and idarubicin. It is at the moment difficult to compare or even compatibilize the effects of the two compounds in their impact on their functions in cancer biology and neurobiology. These remain to be studied in the future by detailed experiments aiming at the elucidation of underlying molecular mechanisms with regard to the two cellular systems. In conclusion, irinotecan and idarubicin activate neurite outgrowth and survival by similar mechanisms as PSA and NCAM, suggesting that they are indeed mimetics of PSA, but with different signaling mechanisms: Erk and PKC signal transduction for neuroprotection and all signal transducers acting on neurite outgrowth, thus dissecting the actions of PSA (see graphical abstract).
